BR112022001492A2 - Anticorpo anti-il17a humanizado e uso do mesmo - Google Patents

Anticorpo anti-il17a humanizado e uso do mesmo

Info

Publication number
BR112022001492A2
BR112022001492A2 BR112022001492A BR112022001492A BR112022001492A2 BR 112022001492 A2 BR112022001492 A2 BR 112022001492A2 BR 112022001492 A BR112022001492 A BR 112022001492A BR 112022001492 A BR112022001492 A BR 112022001492A BR 112022001492 A2 BR112022001492 A2 BR 112022001492A2
Authority
BR
Brazil
Prior art keywords
il17a
antibody
humanized
ability
present
Prior art date
Application number
BR112022001492A
Other languages
English (en)
Inventor
Chunyun Sun
Jing Li
Liangzhi Xie
Tianjiao Liu
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of BR112022001492A2 publication Critical patent/BR112022001492A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

anticorpo anti-il17a humanizado e uso do mesmo. a presente invenção pertence ao campo de imunoterapia de doenças autoimunes e refere-se a um anticorpo monoclonal humanizado que se liga a il17a. a presente invenção revela uma sequência de ácidos nucleicos que codifica o dito anticorpo (que inclui regiões variáveis de cadeia pesada/leve), um vetor que contém as ditas sequências de ácidos nucleicos, uma composição farmacêutica e um kit. o dito anticorpo monoclonal tem capacidade de se ligar especificamente à proteína il17a com alta afinidade, tem uma forte capacidade de bloquear a ligação de il17a, il17a/f ao il17ra receptor. em comparação a fármacos comparáveis, o dito anticorpo tem capacidade superior ou equivalente de bloquear secreção de citocina inflamatória induzida por il17a e il17a/f de fibroblastos epidérmicos humanos hff; em um modelo de psoríase de camundongo, o dito anticorpo também mostrou eficácia in vivo significativamente melhor do que fármacos comparáveis, e a administração do dito anticorpo reduziu significativamente pontuações de pasi; no estudo de eficácia de macaco cinomolgo, o dito anticorpo humanizado demonstrou farmacocinética superior, incluindo rápida absorção após injeção subcutânea, longa meia-vida e melhor exposição a fármaco, etc., criando bases para ciclos de dosagens maiores. o anticorpo monoclonal humanizado da presente invenção pode ser usado para o tratamento de psoríase, etc.
BR112022001492A 2019-07-26 2020-07-24 Anticorpo anti-il17a humanizado e uso do mesmo BR112022001492A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910682988 2019-07-26
PCT/CN2020/104448 WO2021018035A1 (zh) 2019-07-26 2020-07-24 人源化抗il17a抗体及其应用

Publications (1)

Publication Number Publication Date
BR112022001492A2 true BR112022001492A2 (pt) 2022-03-22

Family

ID=74230189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001492A BR112022001492A2 (pt) 2019-07-26 2020-07-24 Anticorpo anti-il17a humanizado e uso do mesmo

Country Status (10)

Country Link
US (1) US20220144936A1 (pt)
EP (1) EP4036113A4 (pt)
JP (1) JP7214921B2 (pt)
KR (1) KR20220071179A (pt)
CN (1) CN114286827B (pt)
AU (1) AU2020322569A1 (pt)
BR (1) BR112022001492A2 (pt)
CA (1) CA3148491C (pt)
MX (1) MX2022001068A (pt)
WO (1) WO2021018035A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380906B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN117843801A (zh) * 2023-12-29 2024-04-09 北京贝来药业有限公司 以白介素家族成员为靶点的新型抗体以及下游产品
CN117866902B (zh) * 2024-03-12 2024-06-04 北京贝来生物科技有限公司 具有抗il-17a活性的基因修饰干细胞及其制备方法以及药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2481753B1 (en) 2005-12-13 2018-04-18 Eli Lilly and Company Anti-IL-17 Antibodies
WO2009147362A1 (en) * 2008-06-03 2009-12-10 Imperial Innovations Limited Method of rheumatoid arthritis treatment
SG11201505330QA (en) * 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014161570A1 (en) * 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
WO2018236728A1 (en) * 2017-06-18 2018-12-27 Kindred Biosciences, Inc. ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
EP3672988A1 (en) 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
CN109679920B (zh) * 2018-12-26 2019-11-22 北京贝来生物科技有限公司 一种表达il-17a信号通路阻断剂的间充质干细胞
CN110003337B (zh) * 2019-04-12 2023-05-09 深圳普瑞金生物药业股份有限公司 Il17ra单域抗体、核酸及试剂盒

Also Published As

Publication number Publication date
CA3148491A1 (en) 2021-02-04
WO2021018035A1 (zh) 2021-02-04
US20220144936A1 (en) 2022-05-12
KR20220071179A (ko) 2022-05-31
CN114286827A (zh) 2022-04-05
JP7214921B2 (ja) 2023-01-30
CN114286827B (zh) 2024-01-12
AU2020322569A1 (en) 2022-02-17
EP4036113A4 (en) 2023-01-18
JP2022535151A (ja) 2022-08-04
EP4036113A1 (en) 2022-08-03
MX2022001068A (es) 2022-02-14
CA3148491C (en) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112022001492A2 (pt) Anticorpo anti-il17a humanizado e uso do mesmo
ES2579768T3 (es) Anticuerpos anti-KIR, formulaciones y usos de los mismos
AU2015370522B2 (en) Pharmaceutical products and stable liquid compositions of IL-17 antibodies
BRPI0905076B8 (pt) anticorpo anti-receptor de il-6, gene e composição farmacêutica compreendendo o mesmo
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
AU2017351183B2 (en) Anti-IL-33 antibodies and uses thereof
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
JP2018507202A (ja) モノクローナル抗体のための安定的な液体製剤
EP3689370A1 (en) Anti-gdf15 antibodies
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
RS52004B (en) ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION
CN106039306A (zh) 使用针对TNFα的单结构域抗体治疗免疫病症的方法
CN103732622A (zh) 抗神经生长因子抗体及其制备和使用方法
BR112016020643A2 (pt) anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos
TWI639440B (zh) 包括ｇｍ－ｃｓｆ中和化合物之液態配方
JP2019517508A5 (pt)
JP2018515493A5 (pt)
SG193963A1 (en) Formulations with reduced viscosity
BR112021023501A2 (pt) Formulações estabilizadas contendo anticorpos anti-angptl3
TW201439118A (zh) Ｂｍｐ－６抗體
AR045765A1 (es) Moleculas de union a cd45 y uso terapeutico
WO2014141064A1 (en) Notch2 binding molecules for treating respiratory diseases
BR112021018727A2 (pt) Formulações estabilizadas que contêm anticorpos anti il 33